The offering is highly dilutive, over 12 million new shares issued at $142 represents ~8.5% dilution assuming ~143 million prior shares outstanding. While the cash strengthens the balance sheet for late-stage trials, the scale of dilution outweighs benefits in the near term. Traders should monitor short-term price pressure and assess whether future R&D milestones can offset sentiment around dilution.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $146.23entry
- T+1 · 7mo ago +1.83%α +2.48% · $148.90
- T+5 · 7mo ago −9.96%α −10.87% · $131.67
- T+20 · 6mo ago −1.27%α −5.47% · $144.37
- T+60 · 4mo ago +26.13%α +19.35% · $184.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of common stock and convertible notes, with net proceeds of $2.137 billion. The capital raise includes 12.15 million shares at $142 per share and $500 million in 0.50% convertible senior notes due 2033, marking a significant dilutive financing event. The funds will support R&D and commercialization efforts for its RAS-addicted cancer therapies.
Key Financial Metrics
Key Facts
- Closed concurrent public offerings: 12,147,887 shares of common stock at $142/share and $500 million in 0.50% convertible senior notes due 2033
- Gross proceeds: $2.225 billion; net proceeds: $2.137 billion after underwriting discounts and expenses
- Convertible notes have a 0.50% coupon, mature May 1, 2033, and initial conversion price of $198.80 per share (40% premium to stock offering price)
- Proceeds to be used for R&D, potential commercialization, G&A, and capital expenditures
- J.P. Morgan, TD Cowen, and Guggenheim Securities acted as book-running managers
Financial Impact
Approximately $2.137 billion in net proceeds, but with substantial near-term dilution from equity issuance and potential future dilution from convertible notes
Risk Factors
- Significant shareholder dilution from equity issuance
- Future equity conversion risk from notes if stock price rises, increasing potential share count by ~2.5 million at initial conversion rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276479 |
Track record
44 reports on RVMD
7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers